SUSPECT ADVERSE REACTION REPORT

PA-Tolmar-TLM-2025-04614

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year			Day	Month	Year
F-G	PANAMA	21	Jan	1939	86	Male			

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Death (Death (10011906), Death (10011906))
(- /Jun/2025) - Fatal

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- [x] PATIENT DIED
- [ ] LIFE THREATENING
- [ ] INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- [ ] RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- [ ] CONGENITAL ANOMALY
- [ ] OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? [ ] YES [ ] NO [x] NA

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 6 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION [ ] YES [ ] NO [x] NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (12/Aug/2020 -)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
[ ] YES [ ] NO	PA-Tolmar-TLM-2025-04614
24c. DATE RECEIVED BY MANUFACTURER: 10/Jul/2025	24d. REPORT SOURCE: [x] STUDY [ ] LITERATURE [ ] HEALTH PROFESSIONAL
DATE OF THIS REPORT: 15/Jul/2025	25a. REPORT TYPE: [x] INITIAL [ ] FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Panama was received by Adium via Patient Support Program "Asofarma a tu Lado" (Reference number: PA-ADIUM-PA-0071-20250710) on 10-Jul-2025 from a consumer (non-healthcare professional) regarding an elderly male patient who experienced a serious event of "death" (Death) during Eligard (leuprolide acetate) 45 mg therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 11-Jul-2025.

The patient's medical history was unknown and current condition included prostate cancer.

Concomitant medications were unknown.

On 12-Aug-2020, the patient began to receive Eligard (leuprolide acetate) 45 mg, every 6 months via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not provided).

On an unknown date in Jun-2025, the patient died. The cause of death was unknown. The patient was 86-year-old at the time of his death. It was unknown if an autopsy was performed. No further details were available.

Action taken with Eligard in response to the event death was not applicable. De-challenge and re-challenge were not applicable.

The outcome of the event death was fatal.

The reporter assessed the seriousness of the event death as serious (death).

The reporter assessed the causality of the event death as not related in relationship to Eligard and Eligard unspecified device.

No further information is expected as consent to be contacted was not provided.

Listedness
Death >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Death> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Death> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Death> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an elderly 86-year-old male patient who reportedly died (Death) during Eligard (leuprolide acetate) 45 mg therapy for prostate cancer. Tolmar assessed death as serious due to fatal outcome. Causal role of Eligard (drug component) in the patient's death was not assessable as lack of information regarding cause of death, events or circumstances preceding patient's death, autopsy report, relevant medical history, supportive investigations that could indicate cause of death, concomitant medications received by the patient precludes meaningful medical assessment of the report. However, advanced age of the patient and underlying prostate cancer were pre-existing risk factors for the patient's death. Death was assessed as not related to the device component of Eligard.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) Unknown
Daily Dose	:	(45 milligram(s), 1 in 6 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates	:	1) From : 12/Aug/2020 To :Not applicable
Action(s) Taken With Drug	:	Not applicable

Causality

1) Death (Death - 10011906, Death - 10011906)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Not assessable
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

Continuation Sheet for CIOMS report

1) Death
CORE UnLabeled

2) Drug	:	Eligard® Unspecified Device (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) Unknown
Route of Admin	:	1) Subcutaneous
Indications	:	1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates	:	1) From : 12/Aug/2020 To :Not applicable
Action(s) Taken With Drug	:	Not applicable

Causality

1) Death (Death - 10011906, Death - 10011906)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) Death
CORE